Kanwa, an investment vehicle affiliated of Barings, a financial services firms, completed the acquisition of Midatech Pharma's US commercial arm, that focuses on the research and development of medicines for rare cancers, via both in house programmes as well as partnered programme, for $19m. "The divestment of Midatech's US commercial arm will allow us to streamline and reshape the business from a specialty pharma to a pure play biotech company, and focus all our energy, attention and resources on advancing our innovative, higher value R&D oncology pipeline. Our technologies have recently reached key validation milestones in their development and following completion we intend to accelerate this momentum for our programs and platforms as we look to unlock the full value of our pipeline and address diseases with desperate unmet medical needs," Craig Cook, Midatech Pharma CEO.